Rennard, S.I., Fogarty, C., Kelsen, S., Long, W., Ramsdell, J., Allison, J., Mahler, D., Saadeh, C., Siler, T., Snell, P., Korenblat, P., Smith, W., Kaye, M., Mandel, M., Andrews, C., Prabhu, R., Donohue, J.F., Watt, R., Lo, K.H., Schlenker-Herceg, R., Barnathan, E.S. and Murray, J. (2007) COPD Investigators. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Journal of Respiratory and Critical Care Medicine, 175, 926-934. doi:10.1164/rccm.200607-995OC

has been cited by the following article:

• TITLE: Bronchial hyperreactivity: pathogenesis and treatment options

  AUTHORS: Martina Antosova, Anna Strapkova, Jana Plevkova

  KEYWORDS: Airway Hyperreactivity; Inflammatory Mediators; Nervous System; Therapeutic Targets

  JOURNAL NAME: Open Journal of Molecular and Integrative Physiology, Vol.1 No.3, November 4, 2011

  ABSTRACT: This review is written to summarize and critically analyze pathogenesis of bronchial hyperreactivity (BHR) as an underlying outcome for suitable treatment options. It describes and discusses the role of genetic predisposition, inflammatory mediators and other endogenous factors (growth factors, nuclear transcription factors), neural regulation and proinflammatory neurotransmitter in the pathogenesis of BHR. Based on these data it provides brief insight into the treatment options, which could be applied to minimize symptoms of respiratory diseases characterized by BHR and successfully diminish the pathogenesis pathways involved.